PriceTargets.com logo

NASDAQ:SYRS - Syros Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.57
  • Forecasted Upside: 109.18 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$8.40 As of 02/26/2021 01:00 AM ET
▼ -0.48 (-5.41%)
1 month | 3 months | 12 months
Get New Syros Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYRS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$17.57
▲ +109.18% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Syros Pharmaceuticals in the last 3 months. The average price target is $17.57, with a high forecast of $20.00 and a low forecast of $13.00. The average price target represents a 109.18% upside from the last price of $8.40.
Buy
The current consensus among 8 contributing investment analysts is to buy stock in Syros Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2020Brookline Capital ManagementInitiated CoverageBuy$19.00Low
i
Rating by L. Cann at Brookline Capital Management
11/6/2020OppenheimerInitiated CoverageBuy$13.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/4/2020HC WainwrightUpgradeNeutral ➝ Buy$11.00 ➝ $15.00High
i
Rating by A. Fein at HC Wainwright
10/26/2020Roth CapitalBoost Price TargetBuy$17.00 ➝ $20.00High
i
10/25/2020OppenheimerInitiated CoverageBuy$13.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
9/22/2020Alliance Global PartnersInitiated CoverageBuy$18.00Medium
i
8/10/2020HC WainwrightReiterated RatingHold$11.00Medium
i
8/7/2020Piper SandlerBoost Price Target$14.00 ➝ $18.00Medium
i
8/6/2020JMP SecuritiesBoost Price TargetOutperform$16.00 ➝ $20.00Low
i
6/1/2020OppenheimerInitiated CoverageBuy$11.00Medium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
5/29/2020Piper SandlerBoost Price TargetOverweight$12.00 ➝ $14.00Low
i
5/8/2020HC WainwrightReiterated RatingHoldHigh
i
5/7/2020OppenheimerReiterated RatingBuy$11.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
3/6/2020HC WainwrightReiterated RatingNeutral$10.00 ➝ $8.00High
i
Rating by Andrew Fein at HC Wainwright
3/5/2020CowenReiterated RatingBuyHigh
i
1/17/2020WedbushDowngradeOutperform ➝ Neutral$9.00High
i
Rating by D. Nierengarten at Wedbush
12/18/2019CowenReiterated RatingBuyHigh
i
11/13/2019HC WainwrightReiterated RatingHold$10.00High
i
Rating by Andrew Fein at HC Wainwright
11/12/2019CowenReiterated RatingBuyHigh
i
10/24/2019CowenReiterated RatingBuyLow
i
10/18/2019HC WainwrightSet Price TargetHold$10.00High
i
Rating by Andrew Fein at HC Wainwright
10/18/2019JMP SecuritiesLower Price TargetMarket Outperform$18.00 ➝ $16.00Medium
i
10/17/2019Piper Jaffray CompaniesLower Price Target$24.00 ➝ $18.00High
i
7/12/2019Roth CapitalInitiated CoverageBuy$17.00High
i
Rating by Zegbeh Jallah at Roth Capital
5/2/2019HC WainwrightReiterated RatingNeutralLow
i
Rating by A. Fein at HC Wainwright
4/25/2019WedbushReiterated RatingOutperform$13.00Low
i
4/10/2019Piper Jaffray CompaniesLower Price TargetOverweight$28.00 ➝ $24.00Low
i
3/8/2019Roth CapitalSet Price TargetBuy$14.00High
i
Rating by Jotin Marango at Roth Capital
3/8/2019JMP SecuritiesReiterated RatingMkt Outperform ➝ Mkt Outperform$18.00High
i
Rating by Konstantinos Aprilakis at JMP Securities
3/8/2019HC WainwrightReiterated RatingHold$10.00High
i
3/7/2019OppenheimerSet Price TargetBuy$13.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
2/14/2019OppenheimerReiterated RatingOutperform$13.00 ➝ $13.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/3/2018WedbushReiterated RatingOutperform$13.00High
i
12/2/2018Roth CapitalSet Price TargetBuy$14.00High
i
Rating by Jotin Marango at Roth Capital
11/15/2018Roth CapitalSet Price TargetBuy$12.00Low
i
Rating by Jotin Marango at Roth Capital
11/13/2018OppenheimerSet Price TargetBuy$26.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
11/5/2018Roth CapitalUpgradeNeutral ➝ Buy$12.00Medium
i
Rating by Jotin Marango at Roth Capital
11/1/2018JMP SecuritiesSet Price TargetBuy$33.00High
i
Rating by Konstantinos Aprilakis at JMP Securities
11/1/2018OppenheimerSet Price TargetBuy$26.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
8/8/2018HC WainwrightReiterated RatingHold$10.00Low
i
Rating by A. Fein at HC Wainwright
7/17/2018CowenReiterated RatingBuyMedium
i
3/14/2018HC WainwrightReiterated RatingHold$10.00High
i
Rating by A. Fein at HC Wainwright
3/13/2018WedbushReiterated RatingOutperform ➝ Outperform$11.00 ➝ $13.00High
i
1/8/2018OppenheimerSet Price TargetBuy$28.00High
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/21/2017HC WainwrightReiterated RatingHold$10.00Low
i
12/13/2017OppenheimerSet Price TargetBuy$28.00Medium
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/11/2017CowenReiterated RatingBuyHigh
i
12/7/2017OppenheimerReiterated RatingBuy$28.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
10/31/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$30.00N/A
i
10/23/2017Roth CapitalInitiated CoverageNeutral ➝ Neutral$15.00N/A
i
Rating by J. Marango at Roth Capital
9/28/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$33.00High
i
8/10/2017WedbushReiterated RatingOutperform$25.00 ➝ $22.84Medium
i
8/10/2017JMP SecuritiesDowngradeOutperform ➝ Market PerformMedium
i
8/9/2017CowenReiterated RatingBuyHigh
i
6/12/2017OppenheimerSet Price TargetBuy$28.00High
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
5/16/2017WedbushReiterated RatingOutperform$22.00High
i
4/12/2017OppenheimerReiterated RatingOutperform$28.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
3/20/2017WedbushReiterated RatingOutperform$22.00 ➝ $18.00High
i
2/27/2017OppenheimerSet Price TargetBuy$28.00N/A
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/15/2016OppenheimerReiterated RatingBuy$28.00N/A
i
11/29/2016OppenheimerInitiated CoverageOutperform$28.00N/A
i
11/14/2016Piper Jaffray CompaniesSet Price TargetBuy$20.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
11/14/2016WedbushReiterated RatingOutperform$18.00N/A
i
9/22/2016Piper Jaffray CompaniesReiterated RatingBuy$20.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
9/9/2016HC WainwrightReiterated RatingHold$10.00N/A
i
Rating by Andrew Fein at HC Wainwright
7/25/2016CowenInitiated CoverageOutperformN/A
i
7/25/2016JMP SecuritiesInitiated CoverageOutperform$22.00N/A
i
7/25/2016WedbushInitiated CoverageOutperform$18.00N/A
i
Rating by D. Nierengarten at Wedbush
7/25/2016Piper Jaffray CompaniesInitiated CoverageOverweight$20.00N/A
i
7/18/2016HC WainwrightInitiated CoverageNeutral$10.00N/A
i
Rating by A. Fein at HC Wainwright
(Data available from 2/28/2016 forward)
Syros Pharmaceuticals logo
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $8.40
$8.21
$9.34

50 Day Range

MA: $11.89
$8.88
$14.95

52 Week Range

Now: $8.40
$4.26
$15.65

Volume

917,813 shs

Average Volume

740,532 shs

Market Capitalization

$472.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Syros Pharmaceuticals?

The following sell-side analysts have issued research reports on Syros Pharmaceuticals in the last twelve months: Alliance Global Partners, Brookline Capital Management, Cowen Inc, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for SYRS.

What is the current price target for Syros Pharmaceuticals?

7 Wall Street analysts have set twelve-month price targets for Syros Pharmaceuticals in the last year. Their average twelve-month price target is $17.57, suggesting a possible upside of 109.2%. JMP Securities has the highest price target set, predicting SYRS will reach $20.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $13.00 for Syros Pharmaceuticals in the next year.
View the latest price targets for SYRS.

What is the current consensus analyst rating for Syros Pharmaceuticals?

Syros Pharmaceuticals currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SYRS will outperform the market and that investors should add to their positions of Syros Pharmaceuticals.
View the latest ratings for SYRS.

What other companies compete with Syros Pharmaceuticals?

Other companies that are similar to Syros Pharmaceuticals include Madrigal Pharmaceuticals, NGM Biopharmaceuticals, ADC Therapeutics, Endo International, Aurinia Pharmaceuticals, Pandion Therapeutics, Revance Therapeutics, Seres Therapeutics, Shattuck Labs, Arcutis Biotherapeutics, Zentalis Pharmaceuticals, Applied Molecular Transport, ImmunoGen, PMV Pharmaceuticals and Praxis Precision Medicines.

How do I contact Syros Pharmaceuticals' investor relations team?

Syros Pharmaceuticals' physical mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company's listed phone number is 617-744-1340 and its investor relations email address is [email protected] The official website for Syros Pharmaceuticals is www.syros.com.